Posts tagged New York
Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20.

Read More
Dresner Partners opens office in Florida

Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice.  Mr. Stern will also continue to spend a portion of his time in Dresner’s New York office.   

Dresner is a leading, FINRA-registered, middle-market investment bank focused on mergers and acquisitions, as well as capital raising and valuations to closely-held, family-owned and sponsor-backed companies for over 25 years.

Read More
Titan’s Probuphine gains media attention in NYC

New York’s WPIX-TV has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction.

Read More
Titan’s Probuphine attracts more media attention

The New York Times has published an article about addiction medicines that includes a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction.

The article quotes Richard Rosenthal, medical director of addiction psychiatry at Mount Sinai Behavioral Health System in New York, who discusses how Probuphine solves three problems associated with opioid maintenance therapy.  The first is the chance of resale or accidental exposure to the pills. “Also, there’s the opportunity for non-adherence — people forget, or don’t take their dose, which leaves them vulnerable again,” he said.  “The other issue mentioned is that medicines have peaks and troughs. “People on various medications may have increased cravings during those troughs.”

Read More